Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Canopy Growth Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Canopy Growth Corp trades at $1 (market cap $421.10M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 22.4× Canopy Growth Corp's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| BIO | CGC | |
|---|---|---|
Market Cap | $9.43B | $421.10M |
Sector | Health | Health |
52-Week High | $356.25 | $1.92 |
52-Week Low | $241.71 | $0.86 |
Enterprise Value | $9.18B | $378.55M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
